FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247497787> ?p ?o ?g. }

• W2247497787 endingPage "6508" @default.
• W2247497787 startingPage "6508" @default.
• W2247497787 abstract "6508 Background: Dasatinib (BMS-354825) is a novel, oral, multi-targeted kinase inhibitor of BCR-ABL and SRC kinases with proven preclinical and clinical activity against imatinib resistant BCR-ABL mutations. Methods: CA180013 is an open-label Phase II study of dasatinib in imatinib-resistant (IM-R) or -intolerant (IM-I) patients (pts) with CP-CML. Between February-August 2005, 424 pts were recruited from 75 centers worldwide. Dasatinib was given at 70 mg twice daily (BID) with dose escalation to 90 mg BID in pts lacking response, and dose reductions to 50 and 40 mg BID for toxicity. Evaluations were weekly blood counts for the first 12 weeks; bone marrow cytology and cytogenetics every 3 months. The primary endpoint was rate of major cytogenetic response (MCyR; ≤35% Philadelphia pos. metaphases) in IM-R pts. Results: Data are currently available from the first 186 pts (127 IM-R, 59 IM-I) accrued prior to May 12, 2005. Median age was 59 yrs (range 24–79); 46% were male. Median time from diagnosis of CML was 64 months. Of the IM-R pts, 72% received IM >3 yrs, and 72% had >600 mg/day of IM. Overall, 70% had received prior interferon alpha. 62 (33%) pts achieved a prior MCyR to IM. With ≥6 months of follow up, 168 (90%) pts had a complete hematologic response (CHR). MCyR were achieved in 83 (45%) pts including 40 (31%) of IM-R pts, and 43 (73%) of IM-I pts. Mutations in the BCR-ABL domain were found in 65/176 (37%) pts; 57 (88%) achieved CHR, and 24 (37%) MCyR. Molecular response analysis is ongoing. 160 (86%) pts remain on study without progression. Grade 3/4 neutropenia or thrombocytopenia was reported in 83 (45%) pts and 85 (46%) pts with onset after 4–8 weeks of therapy in most pts. Temporary dose interruptions occurred in 146 (78%), and dose reductions in 96 (52%) pts with a median daily of 108 (range 19–169) mg. Non-hematologic toxicity consisted mainly of Grade 1/2 diarrhea, headache, superficial edema, and pleural effusion, with ≤2% Grade 3/4. There was no cross-intolerance between dasatinib and IM. Conclusions: Dasatinib demonstrated substantial hematologic and cytogenetic activity in IM-R and IM-I pts with CP-CML. An updated analysis of 424 pts with ≥6 months of follow up will be presented. [Table: see text]" @default.
• W2247497787 created "2016-06-24" @default.
• W2247497787 creator A5014558902 @default.
• W2247497787 creator A5018111458 @default.
• W2247497787 creator A5020371571 @default.
• W2247497787 creator A5035964802 @default.
• W2247497787 creator A5043294402 @default.
• W2247497787 creator A5044098380 @default.
• W2247497787 creator A5044224344 @default.
• W2247497787 creator A5045437866 @default.
• W2247497787 creator A5050195308 @default.
• W2247497787 creator A5084379902 @default.
• W2247497787 date "2006-06-20" @default.
• W2247497787 modified "2023-09-26" @default.
• W2247497787 title "Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 ’START-C’ Study" @default.
• W2247497787 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.6508" @default.
• W2247497787 hasPublicationYear "2006" @default.
• W2247497787 type Work @default.
• W2247497787 sameAs 2247497787 @default.
• W2247497787 citedByCount "21" @default.
• W2247497787 countsByYear W22474977872012 @default.
• W2247497787 crossrefType "journal-article" @default.
• W2247497787 hasAuthorship W2247497787A5014558902 @default.
• W2247497787 hasAuthorship W2247497787A5018111458 @default.
• W2247497787 hasAuthorship W2247497787A5020371571 @default.
• W2247497787 hasAuthorship W2247497787A5035964802 @default.
• W2247497787 hasAuthorship W2247497787A5043294402 @default.
• W2247497787 hasAuthorship W2247497787A5044098380 @default.
• W2247497787 hasAuthorship W2247497787A5044224344 @default.
• W2247497787 hasAuthorship W2247497787A5045437866 @default.
• W2247497787 hasAuthorship W2247497787A5050195308 @default.
• W2247497787 hasAuthorship W2247497787A5084379902 @default.
• W2247497787 hasConcept C126322002 @default.
• W2247497787 hasConcept C143998085 @default.
• W2247497787 hasConcept C2777583451 @default.
• W2247497787 hasConcept C2778729363 @default.
• W2247497787 hasConcept C2779536868 @default.
• W2247497787 hasConcept C3019892230 @default.
• W2247497787 hasConcept C71924100 @default.
• W2247497787 hasConcept C90924648 @default.
• W2247497787 hasConceptScore W2247497787C126322002 @default.
• W2247497787 hasConceptScore W2247497787C143998085 @default.
• W2247497787 hasConceptScore W2247497787C2777583451 @default.
• W2247497787 hasConceptScore W2247497787C2778729363 @default.
• W2247497787 hasConceptScore W2247497787C2779536868 @default.
• W2247497787 hasConceptScore W2247497787C3019892230 @default.
• W2247497787 hasConceptScore W2247497787C71924100 @default.
• W2247497787 hasConceptScore W2247497787C90924648 @default.
• W2247497787 hasIssue "18_suppl" @default.
• W2247497787 hasLocation W22474977871 @default.
• W2247497787 hasOpenAccess W2247497787 @default.
• W2247497787 hasPrimaryLocation W22474977871 @default.
• W2247497787 hasRelatedWork W1548870648 @default.
• W2247497787 hasRelatedWork W1975185750 @default.
• W2247497787 hasRelatedWork W200163820 @default.
• W2247497787 hasRelatedWork W2024021544 @default.
• W2247497787 hasRelatedWork W2029456196 @default.
• W2247497787 hasRelatedWork W2032615307 @default.
• W2247497787 hasRelatedWork W2566175026 @default.
• W2247497787 hasRelatedWork W2578703009 @default.
• W2247497787 hasRelatedWork W2904392588 @default.
• W2247497787 hasRelatedWork W4230849756 @default.
• W2247497787 hasVolume "24" @default.
• W2247497787 isParatext "false" @default.
• W2247497787 isRetracted "false" @default.
• W2247497787 magId "2247497787" @default.
• W2247497787 workType "article" @default.